Paper Details

  1. Home
  2. Paper Details

Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease.

Author: GrossbergG T, MengX, OlinJ T, SomogyiM

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Rivastigmine patches higher than 9.5 mg/24 h may offer additional benefits in treating mild-to-moderate Alzheimer’s disease. The 13.3 mg/24 h patch is worthy of further investigation.
Paper Details　
Original Abstract of the Article :
AIM: The cholinesterase inhibitor rivastigmine is available in both oral and transdermal forms. The efficacy of oral rivastigmine appears to be dose-dependent. The current analysis investigates the effect of dose on the efficacy of the rivastigmine transdermal patch. METHODS: This was a retrospecti...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1742-1241.2011.02641.x

データ提供：米国国立医学図書館（NLM）

Rivastigmine Patches: A Dose-Dependent Journey for Alzheimer's Disease

The search for effective treatments for Alzheimer's disease is a continuous quest. This study investigated the dose-dependent effects of rivastigmine, a medication used to treat Alzheimer's disease, in its transdermal patch form. The researchers used a large clinical trial, like a grand caravan traversing a vast desert, to examine the effects of different rivastigmine patch doses on individuals with mild-to-moderate Alzheimer's disease.

The study found that higher doses of the rivastigmine patch were associated with greater improvements in cognitive function and daily living activities in individuals with Alzheimer's disease. The findings suggest that higher doses may offer additional benefits compared to lower doses.

Dosage Matters: A Key Finding

The findings suggest that the effectiveness of rivastigmine patches is dose-dependent, with higher doses potentially providing greater benefits for individuals with Alzheimer's disease. This emphasizes the importance of individualizing treatment based on patient needs and response.

Navigating Alzheimer's Treatment

This research highlights the importance of careful dose selection in managing Alzheimer's disease. The study demonstrates that the effectiveness of rivastigmine patches is influenced by the dose, suggesting the need for individualized treatment strategies.

Dr.Camel's Conclusion

This study highlights the need for personalized approaches to managing Alzheimer's disease, with careful consideration of the appropriate dose of medication. The findings underscore the importance of ongoing research and development of new treatment options for this challenging condition.

Date :
  1. Date Completed 2011-12-22
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

21309961

DOI: Digital Object Identifier

10.1111/j.1742-1241.2011.02641.x

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.